182 related articles for article (PubMed ID: 34267347)
21. Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide.
Lu L; Dong J; Wang L; Xia Q; Zhang D; Kim H; Yin T; Fan S; Shen Q
Oncogene; 2018 Sep; 37(39):5292-5304. PubMed ID: 29855616
[TBL] [Abstract][Full Text] [Related]
22. Osthole inhibits triple negative breast cancer cells by suppressing STAT3.
Dai X; Yin C; Zhang Y; Guo G; Zhao C; Wang O; Xiang Y; Zhang X; Liang G
J Exp Clin Cancer Res; 2018 Dec; 37(1):322. PubMed ID: 30577812
[TBL] [Abstract][Full Text] [Related]
23. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
[TBL] [Abstract][Full Text] [Related]
24. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
25. Bt354 as a new STAT3 signaling pathway inhibitor against triple negative breast cancer.
Chen Y; Ji M; Zhang S; Xue N; Xu H; Lin S; Chen X
J Drug Target; 2018 Dec; 26(10):920-930. PubMed ID: 29595328
[TBL] [Abstract][Full Text] [Related]
26. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
Qin JJ; Yan L; Zhang J; Zhang WD
J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
[TBL] [Abstract][Full Text] [Related]
27. Noncanonical pS727 post translational modification dictates major STAT3 activation and downstream functions in breast cancer.
Dimri S; Malhotra R; Shet T; Mokal S; Gupta S; De A
Exp Cell Res; 2020 Nov; 396(2):112313. PubMed ID: 33002501
[TBL] [Abstract][Full Text] [Related]
28. Ilamycin C induces apoptosis and inhibits migration and invasion in triple-negative breast cancer by suppressing IL-6/STAT3 pathway.
Xie Q; Yang Z; Huang X; Zhang Z; Li J; Ju J; Zhang H; Ma J
J Hematol Oncol; 2019 Jun; 12(1):60. PubMed ID: 31186039
[TBL] [Abstract][Full Text] [Related]
29. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733
[TBL] [Abstract][Full Text] [Related]
30. Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression.
Li LX; Zhou JX; Calvet JP; Godwin AK; Jensen RA; Li X
Cell Death Dis; 2018 Feb; 9(3):326. PubMed ID: 29487338
[TBL] [Abstract][Full Text] [Related]
31. Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy.
Feng T; Cao W; Shen W; Zhang L; Gu X; Guo Y; Tsai HI; Liu X; Li J; Zhang J; Li S; Wu F; Liu Y
Oncotarget; 2017 Jan; 8(1):329-344. PubMed ID: 27861147
[TBL] [Abstract][Full Text] [Related]
32. Schisandrin B exhibits potent anticancer activity in triple negative breast cancer by inhibiting STAT3.
Dai X; Yin C; Guo G; Zhang Y; Zhao C; Qian J; Wang O; Zhang X; Liang G
Toxicol Appl Pharmacol; 2018 Nov; 358():110-119. PubMed ID: 30195018
[TBL] [Abstract][Full Text] [Related]
33. Genomic regulation of invasion by STAT3 in triple negative breast cancer.
McDaniel JM; Varley KE; Gertz J; Savic DS; Roberts BS; Bailey SK; Shevde LA; Ramaker RC; Lasseigne BN; Kirby MK; Newberry KM; Partridge EC; Jones AL; Boone B; Levy SE; Oliver PG; Sexton KC; Grizzle WE; Forero A; Buchsbaum DJ; Cooper SJ; Myers RM
Oncotarget; 2017 Jan; 8(5):8226-8238. PubMed ID: 28030809
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA‑124 suppresses cell proliferation and invasion of triple negative breast cancer cells by targeting STAT3.
Shi P; Chen C; Li X; Wei Z; Liu Z; Liu Y
Mol Med Rep; 2019 May; 19(5):3667-3675. PubMed ID: 30896795
[TBL] [Abstract][Full Text] [Related]
35. A new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapy.
Zhang W; Yu W; Cai G; Zhu J; Zhang C; Li S; Guo J; Yin G; Chen C; Kong L
Cell Death Dis; 2018 Oct; 9(11):1098. PubMed ID: 30368518
[TBL] [Abstract][Full Text] [Related]
36. Alantolactone selectively suppresses STAT3 activation and exhibits potent anticancer activity in MDA-MB-231 cells.
Chun J; Li RJ; Cheng MS; Kim YS
Cancer Lett; 2015 Feb; 357(1):393-403. PubMed ID: 25434800
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of STAT3 signaling pathway by nitidine chloride suppressed the angiogenesis and growth of human gastric cancer.
Chen J; Wang J; Lin L; He L; Wu Y; Zhang L; Yi Z; Chen Y; Pang X; Liu M
Mol Cancer Ther; 2012 Feb; 11(2):277-87. PubMed ID: 22203730
[TBL] [Abstract][Full Text] [Related]
38. A cell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro.
Zhao W; Jaganathan S; Turkson J
J Biol Chem; 2010 Nov; 285(46):35855-65. PubMed ID: 20807764
[TBL] [Abstract][Full Text] [Related]
39. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
[TBL] [Abstract][Full Text] [Related]
40. Thymoquinone inhibits proliferation in gastric cancer via the STAT3 pathway in vivo and in vitro.
Zhu WQ; Wang J; Guo XF; Liu Z; Dong WG
World J Gastroenterol; 2016 Apr; 22(16):4149-59. PubMed ID: 27122665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
